HC Wainwright reiterated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $40.00 price target on the biotechnology company’s stock. Capricor Therapeutics Price Performance Shares of CAPR stock opened at $5.05 on Tuesday. Capricor Therapeutics has a 12-month low […]

Roivant Sciences (NASDAQ:ROIV – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $18.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 50.38% from the stock’s previous close. Several […]

HC Wainwright reiterated their buy rating on shares of I-Mab (NASDAQ:IMAB – Free Report) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock. I-Mab Stock Down 2.7 % Shares of NASDAQ:IMAB opened at $1.08 on Tuesday. I-Mab has a fifty-two week low […]

HC Wainwright reissued their buy rating on shares of Korro Bio (NASDAQ:KRRO – Free Report) in a research report released on Tuesday, Benzinga reports. The firm currently has a $100.00 price objective on the stock. KRRO has been the subject of several other research reports. William Blair assumed coverage on shares of Korro Bio in […]

Capricor Therapeutics (NASDAQ:CAPR – Free Report) had its target price boosted by Oppenheimer from $14.00 to $15.00 in a research note published on Tuesday morning, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. A number of other equities research analysts have also recently issued reports on CAPR. Maxim Group reaffirmed […]

Jefferies Financial Group upgraded shares of Relmada Therapeutics (NASDAQ:RLMD – Free Report) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning, MarketBeat Ratings reports. Jefferies Financial Group currently has $13.00 price target on the stock, up from their previous price target of $3.50. Separately, The Goldman […]

LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a neutral rating to a buy rating in a research report report published on Monday morning, MarketBeat Ratings reports. The firm currently has $5.00 price objective on the stock. A number of other research analysts also recently issued reports on the stock. […]

Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) – Research analysts at HC Wainwright lifted their Q3 2024 earnings estimates for shares of Relay Therapeutics in a research report issued to clients and investors on Monday, September 16th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.70) per share for the quarter, […]